Over the past decade, this species has been increasingly recognized as a nosocomial pathogen2)-7). The incidence of pulmonary colonization with P. cepacia has also increased in patients attending certain cystic fibrosis treatment centers and has been correlated with increased morbidity and mortality rates8 11 Relatively little is known about the virulence of P. cepacia23). Because the strains obtained from these patients produced protease and lipase, P. cepacia may damage the pulmonary tissue directly by releasing toxins and enzymes.
In this study, lung infection by P. cepacia was restricted to immunosuppressed animals. Cyclophosphamide treatment predisposed these mice to vigorous proliferation of P. cepacia and probably more concomitant toxin production. Histologically there were numerous bacilli in the pulmonary alveoli, but inflammatory cell infiltration was weak, probably because of cyclophosphamide predisposition.
In addition, treatment of P. cepacia infection is complicated by the almost universal resistance of this organism to commonly used anti-pseudomonal agents24, 25) . Therefore, this model may be useful in helping to establish effective prophylaxis against clinical isolates of P. cepacia.
In conclusion, we believe that this experimental mouse model will be useful for evaluating the pathogenesis and treatment of P. cepacia pneumonia.
